Research Analyst at Independent Analyst
James Amoroso is an independent equity analyst and Managing Director at Independent Analyst, specializing in European pharmaceutical, biotechnology, and healthcare sectors. He is known for his in-depth research on leading firms such as AstraZeneca, Novartis, and Roche, and has developed a track record for identifying sector trends and company turnarounds, though specific public performance rankings or returns are not available. Amoroso began his analyst career in the late 1980s, previously holding roles at major investment banks including UBS, Credit Suisse, and Dresdner Kleinwort Benson before taking on his independent practice. He holds a PhD in Chemistry, has presented at numerous international investor conferences, and has contributed to major sector publications, reflecting his reputation as a credentialed expert in European life sciences equities.
Independent Analyst James Amoroso asked the new CEO, Peter Feld, to share his biggest career achievement and how he accomplished it.
CEO Peter Feld highlighted his work at his previous company, GFK, where he led a successful digitization strategy. He explained that by building a platform for data democratization, he was able to create new relevance and value for customers, a principle he intends to apply at Barry Callebaut, particularly in areas like sustainability.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts